Title：

Osteoporosis Genetic Risk Prediction Using Bone Mineral Density Polygenic Scores in Japanese: TMM CommCohort Study

Author：Yayoi Otsuka-Yamasaki, PhD, DVM[1,2]*, Yoichi Sutoh, PhD[1,2], Tsuyoshi Hachiya, PhD[1,2], Motoki Nakao, PhD, MD[1,3,4], Shiori Minabe, PhD[1,2], Shohei Komaki, PhD[1,2], Hideki Ohmomo, PhD[1,2], Makoto Sasaki,PhD, MD[1,5], and Atsushi Shimizu, PhD[1,2].

[1] Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[2] Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[3] Department of Pharmacology, School of Medicine, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[4] Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan

[5] Division of Ultrahigh field MRI, Institute for Biomedical Sciences, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan.

*Corresponding author; Yayoi Otsuka-Yamasaki
Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan
Tel; +81-011-651-5110

Mail to; yyayo@iwate-med.ac.jp

Data Availability

The QUS-derived T-score GWAS summary statistics are available at jMorp (https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000015). Individual-level data are not publicly available; access may be granted upon request and approval by the Information Distribution Review Committee of the TMM Project.

Funding

This study was supported by the Tohoku Medical Megabank Project of AMED (JP23tm0124006; JP21tm0424601) and JSPS KAKENHI (JP23K09696, YOY and AS).

Conflict of Interest

T.H. is a board member of Genome Analytics Japan, Inc. The other authors declare no conflicts of interest associated with this manuscript.

Ethics Approval

Institutional Review Board of Iwate Medical University gave ethical approval for this work (approval ID: HG H25-2).

Patient Consent:

Written informed consent was obtained from all participants.

Keywords (~ 5 words)

Osteoporosis, Polygenic score, Bone mineral density, Genome-wide association study (GWAS), Japanese population

Abstract

Osteoporosis and related fractures are major health concerns in aging populations. We aimed to develop and validate a polygenic score (PGS) for osteoporosis in a Japanese population using heel quantitative ultrasound (QUS)–derived T-scores. Using genome-wide association study data from 12,371 participants in the Tohoku Medical Megabank Community-Based Cohort, we identified genome-wide significant loci, including *MBL2, TMEM135,* and *WNT16.* PGS models were constructed and evaluated using independent datasets for model selection (n = 1,419) and validation (n = 8,711). Adding the PGS to age and sex resulted in only a modest increase in discrimination (AUC = 0.664 to 0.728) but supported genetic risk stratification. Individuals in the lowest PGS quintile (bottom 20%, genetically high-risk) had an increased risk of osteoporosis (odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.07–1.40), whereas those in the highest PGS quintile (top 20%, genetically low-risk) had a reduced risk (OR = 0.85, 95% CI: 0.71–0.98). Prospective analysis over a mean 3.4-year follow-up confirmed the gradient: the lowest-quintile (high-risk) group had a higher incidence rate ratio (IRR) than the intermediate group (IRR = 1.42, 95% CI: 1.17–1.73), whereas the highest-quintile (low-risk) group had a lower IRR (IRR = 0.70, 95% CI: 0.54–0.89). Age-stratified analyses revealed no statistically significant interaction between age and PGS in predicting osteoporosis, and no differences in the slope of age-related T-score declines across genetic risk groups. Observed T-scores in young adults (20–44 years) and extrapolation to age 20 suggested lower bone status around peak bone mass among genetically high-risk individuals. These findings indicate that a Japanese-specific PGS can stratify osteoporosis risk and may help identify individuals at elevated genetic risk earlier in adulthood.

Lay summaries

We developed a bone mineral density (BMD) genetic score in a large Japanese population and tested whether it can predict osteoporosis. People with scores in the lowest 20% had a higher risk, while those in the highest 20% had a lower risk, and this pattern persisted over 3.4 years of follow-up. The score was not related to how quickly bone density fell with age. Analyses in young adults and projections to age 20 suggested that it mainly reflects differences in peak bone mass, underscoring the importance of early identification and prevention in people at high genetic risk.

Introduction

Osteoporosis and osteoporotic fractures are significant public health concerns associated with impaired activities of daily living, diminished quality of life, and elevated mortality rates.[1] In older adults, fractures frequently necessitate prolonged care, thereby imposing economic burdens, including elevated expenditures for medical care and long-term care services.[2,3] The estimated number of patients with osteoporosis in Japan is approximately 12.8 million, with approximately 193,400 hip fractures occurring annually.[4]

Bone mineral density (BMD) is widely used as an indicator of bone mass, with heritability (the contribution of genetic factors) estimated at 50–80%, indicating a significant influence of genetic factors.[3,5] Bone mass follows a characteristic life-course trajectory, with rapid accrual during childhood and puberty, reaching peak levels in the 20s, remaining relatively stable through midlife, and subsequently declining, particularly after menopause in women.[1,6] As 40–60% of adult bone mass is formed during puberty, peak bone mass is considered a key determinant of the lifelong risk of developing osteoporosis.[6] Achieving and maintaining a higher peak bone mass during growth has been reported to provide a protective effect against osteoporosis in later life.[1,6,7]

Advancements in genome-wide association studies (GWASs) have led to the identification of numerous variants associated with BMD and fracture risk.[5,8] Polygenic scores (PGS), derived from variants associated with BMD, have been developed to predict the genetic risk of osteoporosis and osteoporotic fractures.[5,9]

Recently, an estimated bone mineral density (eBMD) PGS derived from quantitative ultrasound (QUS) measurements was developed using data from the UK Biobank.[5,9] The eBMD-based PGS has been evaluated for its predictive accuracy for osteoporosis and fractures in multiple cohorts, as it shows a negative correlation with osteoporosis and fracture risk.[5,9,10] However, studies have consistently demonstrated that PGS derived from European populations exhibit reduced predictive performance in non-European populations, including East Asians.[10-12] To address this limitation, there is an urgent need to develop PGS models

115 tailored to non-Europeans, including East Asians.[13-17] Chen et al.[17] have tested the multi-
116 ancestry PGS, including Asians in a cohort of Taiwanese people, and demonstrated that it
117 has moderate efficacy, but its performance is not always optimal, and it emphasizes that the
118 development of population-specific PGS is essential in East Asian populations.

119 Concurrently, it has been shown that incorporating modifiable lifestyle factors into a
120 PGS framework may not only predict lifetime risk but also guide targeted prevention
121 strategies.[18] BMD is influenced by both basic and unchangeable environmental factors,
122 such as sex, age, and race, as well as modifiable factors such as calcium intake, smoking,
123 alcohol consumption, physical activity, and sun exposure.[6,19] Even individuals with a high
124 genetic risk for osteoporotic fractures can reduce their risk by adhering to healthy lifestyle
125 habits in European populations.[19]

126 In this study, we developed a PGS for QUS-derived T-score in a Japanese
127 population using data from the Tohoku Medical Megabank (TMM), the largest genome cohort
128 in Japan,[20–22] and evaluated its ability to predict osteoporosis risk. Using a longitudinal
129 design, we assessed genetic and environmental factors at baseline and followed participants
130 over time to capture incident osteoporosis. We stratified participants by PGS, examined its
131 joint effects with non-modifiable and modifiable risk factors, and evaluated its potential as a
132 tool to inform osteoporosis prevention strategies in Japan.

133

134 Materials and Methods

135 Study population

136 TMM Project Community-Based Cohort (TMM CommCohort) has been described
137 in previous studies.[20-22] Participants who visited the evaluation centers in Miyagi and Iwate
138 Prefectures, were grouped into two main cohorts: TMM18K and TMM9K, respectively. The
139 baseline survey was conducted from May 2013 to March 2016, and the secondary survey,
140 conducted 4 years after the baseline, was conducted from May 2017 to March 2020 as part
141 of the ongoing follow-up.

The two cohorts were further divided into four groups based on genotyping with the Axiom Japonica Array v2 (JPAv2)[23,24] or NEO (JPANEO)[25] (TMM18K-JPAv2, TMM18K-JPANEO, TMM9K-JPAv2, and TMM9K-JPANEO) (Figure 1 and Supplementary Table S1). The TMM18K-JPAv2 cohort (n = 12,371) was used to perform QUS-derived T-score GWAS, from which the variant weights for the PGS model were derived. The TMM9K-JPANEO cohort (n = 1,419) was used to identify the best model for predicting osteoporosis. The TMM9K-JPAv2 (n = 7,621) and TMM18K-JPANEO (n = 1,090) cohorts were used for subsequent analyses. All four sample subgroups were independent of one another.

Phenotype definition and measurement

Calcaneal QUS measurements were performed using a Benus device (NIHON KOHDEN, Tokyo, Japan). The device-derived calcaneal T-score was calculated using the manufacturer's young-adult reference (ages 20–40 years). We classified participants as having osteoporosis when the device-derived QUS T-score was ≤ −2.5. Fracture cases were identified based on participants' self-reported history of fractures in the lumbar spine, femur, wrist, or humerus as documented in the questionnaire. Other anthropometric and lifestyle factors, including alcohol intake and smoking history, were obtained from self-reported questionnaires administered at baseline.

Participants who had smoked at least 100 cigarettes in their lifetime were defined as having a "smoking" status. "High alcohol intake" was defined as the consumption of ≥30 g of alcohol per day. "Physical inactivity" was defined as engaging in leisure-time physical activity less than three times per week. "Obesity" was defined as a body mass index (BMI) ≥25 kg/m², calculated from height and weight measured at baseline, in accordance with the local definition in Japan.[26]

Study participants and validation cohort definitions

To evaluate the predictive performance of PGS, we used two independent validation

169 cohorts: TMM9K-JPAv2 (validation cohort I) and TMM18K-JPANEO (validation cohort II). We
170 conducted cross-sectional and prospective analyses based on baseline and follow-up survey
171 data, respectively.

172 For the cross-sectional analysis, we excluded participants with (1) missing T-score
173 values at baseline, (2) extreme baseline T-scores (outside the range −4.0 to +4.0 SD), or (3)
174 missing essential covariates. The final sample included 7,609 participants in validation cohort
175 I and 1,061 participants in validation cohort II (Supplementary Table S1).

176 For the prospective analysis, additional exclusion criteria were applied: (1) no
177 participation in the follow-up survey; (2) baseline T-score ≤−2.5 SD; (3) history of fracture
178 (lumbar spine, femur, wrist, or humerus); (4) self-reported history of osteoporosis at follow-
179 up (due to unclear timing); and (5) extreme baseline T-scores (outside the range −4.0 to +4.0
180 SD). After these exclusions, the prospective subcohorts included 4,811 participants in
181 validation cohort I and 581 participants in validation cohort II (Supplementary Table S1).

182

183 **Genotyping and imputation**

184 It was described in previous studies that the genotyping was performed using either
185 JPAv2 [23,24] or NEO (JPANEO).[25] Participants with a call rate <0.95 and sex discrepancies
186 between genotypic and cohort data were excluded. Genotypes that failed to meet the quality
187 control criteria (call rate <0.99, Hardy–Weinberg equilibrium exact test $P < 1 \times 10^{-5}$, and minor
188 allele frequency <0.01) were also omitted. Pre-phasing and imputation were performed using
189 SHAPEIT2 (r837) and IMPUTE4 (r300.3) with 3.5KJPNv2 haplotype reference panels.[23,28,29]
190 Variant positions in the genome were based on the GRCh37 reference genome.

191

192 **Genome-wide association analysis and annotations**

193 To generate the PGS model, single nucleotide polymorphism weights were
194 estimated using a publicly available GWAS summary of TMM18K-JPAv2 from jMorp (ID:
195 TGA000015; https://jmorp.megabank.tohoku.ac.jp/). Additional methodological details are

196 available on the official website. In brief, GWAS was conducted with BOLT-LMM v2.3.2.[27]
197 Rank-based inverse normalization was applied to reduce the skewness and kurtosis in the
198 T-score distribution. Age, sex, and the first 11 principal components were included as fixed
199 effect covariates.

200 Annotation was performed using an in-house pipeline tailored to the Japanese
201 population. The ToMMo 3.5KJPNv2 reference panel[28] was used to assign allele frequency
202 information and dbSNP identifiers (rsIDs) to variants in the GWAS summary statistics. The
203 gnomAD v2.1 dataset[29] was additionally incorporated to ensure comprehensive rsID
204 annotation and facilitate cross-population comparisons. Regional association plots were
205 generated using LocusZoom (version 0.14.0).[30] Linkage disequilibrium patterns and proxy
206 variants were examined using LDproxy (LDlink, National Cancer Institute)[31] with the 1 KG
207 EAS reference panel.

208

209 **PGS construction and selection**

210 Candidate models were constructed as described previously using three methods:
211 LD pruning and thresholding (P+T), LDpred and polygenic risk score–continuous shrinkage
212 (PRS-CS).[26,32-34] For the P+T method, 24 models were generated using different LD-pruning
213 conditions using one of six parameters for p values (1, 0.5, 5×10^{-2}, 5×10^{-4}, 5×10^{-6}, and
214 5×10^{-8}) and one of four parameters of R^2 values (0.2, 0.4, 0.6, and 0.8). For LDpred, seven
215 models were generated for each Spearman's rank correlation (ρ) value (1, 0.3, 0.1, 0.03,
216 0.01, 0.003, and 0.001). For PRS-CS, six models were generated for each φ value (1×10^{-1},
217 1×10^{-2}, 1×10^{-4}, 1×10^{-6}, 1×10^{-8}, and "auto"). Individual PGSs were calculated using
218 PLINK 2.0 for each model and normalized to Z-scores.

219 In the selection step, TMM9K-JPANEO cohort was used as the dataset for model
220 selection. The model with the highest Spearman rank correlation coefficient (ρ) between the
221 age- and sex-adjusted T-scores and PGS Z-scores was selected.

222 Statistical analyses were performed using R (version 4.2.1). The receiver operating

223 characteristic (ROC) curve and area under the curve (AUC) for the PGS model was estimated
224 using the R package "pROC" (version 1.18.0). The AUCs between the models were
225 compared using DeLong's test.
226
227 **PGS-based risk assessment and stratified analysis**
228 The normalized PGS was divided into quintiles. Cross-sectional associations at
229 baseline were tested using linear regression for continuous outcomes and logistic regression
230 for binary outcomes, adjusting for sex and age. We additionally conducted stratified cross-
231 sectional analyses by baseline age (<65/≥65 years), sex, and major osteoporosis-related risk
232 factors (smoking, alcohol intake, physical activity, and obesity). For these stratified analyses,
233 participants were classified into three genetic risk groups: High (Q1), Intermediate (Q2–Q4),
234 and Low (Q5), using the Intermediate group as the reference category in all comparisons.
235 For prospective analyses, participants without osteoporosis at baseline were
236 followed up for an average of 3.4 years. Because the exact event dates were unavailable,
237 person-time was approximated using the midpoint method: incident cases contributed half of
238 the follow-up duration, while non-cases contributed the full duration. Incidence rates (IRs)
239 per 1,000 person-years and cumulative incidence were estimated by genetic risk group with
240 exact 95% confidence intervals (CI).
241 Results from the two validation cohorts were pooled using the R package "meta"
242 (version 6.2-1). Fixed-effect models were used for the primary meta-analyses. Between-
243 cohort heterogeneity was assessed using Cochran's Q test and the I^2 statistic. Random-
244 effects models (DerSimonian–Laird method) were also fitted, and in the presence of
245 substantial heterogeneity (Q test $P < 0.05$ or $I^2 > 50\%$), were additionally examined as
246 sensitivity analyses to confirm the robustness of the results.
247
248 **Ethical considerations**
249 This research was conducted in accordance with the ethical principles outlined in

the Declaration of Helsinki. All participants provided written informed consent prior to their enrollment. The study protocol was approved by the Institutional Review Board of Iwate Medical University (approval ID: HG H25-2). Analyses using individual-level genomic and phenotypic data were performed on a secure, standalone computational platform operated by the Tohoku Medical Megabank Organization (ToMMo) at Tohoku University (ToMMo Supercomputer System URL; https://sc.megabank.tohoku.ac.jp/).

Data Availability

The QUS-derived T-score GWAS summary has been published in jMorp (https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000015). 3.5KJPNv2 is also available on the jMorp website with a web interface. Due to ethical considerations, including the protection of participant privacy and prevention of unintended identification, individual-level data from the TMM CommCohort Study are not publicly available. Access to these cohorts may be granted upon request and is subject to approval by the Ethics Committee of Iwate Medical University and the Materials and Information Distribution Review Committee of the TMM Project. Researchers interested in accessing these datasets should contact the corresponding author to initiate the request.

Results

Heritable factors for QUS-derived T-score

GWAS was conducted to identify variants associated with the T-score (Supplementary Figure S1A). Variants in three independent loci were above the threshold for the genome-wide significance ($P < 5 \times 10^{-8}$) (Table 1). There were 792 variants above the suggestive line ($P < 1 \times 10^{-5}$) (Supplementary Table S2).

The three loci containing significant variants included genes that had been reported in previous GWASs using QUS-derived T-scores as traits, such as Mannose Binding Lectin 2 (*MBL2*), Transmembrane Protein 135 (*TMEM135*), and *Wnt* Family Member 16 (*WNT16*)

277 [3,5,8] (Table 1). The UK Biobank GWAS summary statistics and GWAS catalog study
278 GCST006433[5] were used for comparison.
279 As shown in Table 1, at the *MBL2* locus, the lead variant in the Japanese GWAS
280 was rs71032654/rs200903639 (del$(TA)_9$CA > dup$(TA)_9$CA), a structural indel. Meanwhile,
281 neither rs71032654 nor rs7908619 was present in the UK Biobank summary statistics (Table
282 1). LocusZoom plots showed recombination hotspots exceeding 30 cM/Mb on either side of
283 rs71032654 (Supplementary Figure S1C). According to the LDproxy results,
284 rs71032654/rs200903639 showed only low LD with surrounding variants (maximum R^2 =
285 0.0687), suggesting that it may represent a distinct signal from previously known tagged
286 variants.
287 Variants in rs2451053 (C>T) in *TMEM135* and rs10254825 (A>G) in *WNT16* were
288 present in both the TMM and UK Biobank cohorts, indicating their similar biological effects
289 on BMD across populations.
290
291 **Determination of the optimal PGS model for T-score measured with QUS**
292 Based on the above GWAS summary, we constructed 37 candidate models to
293 calculate the PGS using three distinct methods (Figure 2A and Supplementary Table S3). We
294 found that the PGS model established by PRS-CS with φ set to "auto" which was composed
295 of 1,012,314 variants, showed the strongest correlation with T-score levels after adjusting for
296 age and sex (Spearman's ρ = 0.147, $P = 2.94 \times 10^{-8}$). Therefore, this model was used for
297 subsequent validation analyses as the best model.
298 Linear regression analysis of baseline T-scores against normalized PGS, adjusted
299 for sex and age, revealed a significant positive association in validation cohorts I (Estimate
300 = 0.090, $P = 1.19 \times 10^{-15}$, Adjusted R^2 = 0.237), and II (Estimate = 0.098, P = 0.001, Adjusted
301 R^2 = 0.204) (Figure 2B and Supplementary Table S4).
302
303 **Predictive performance and association of T-score PGS with osteoporosis**

To investigate the predictive utility of PGS for osteoporosis, we evaluated the model's performance after including PGS in addition to sex and age. In validation cohort I, there were 1,286 cases of osteoporosis out of 7,609, and in validation cohort II, there were 233 cases of osteoporosis in 1,061 patients (Supplementary Table S5). In validation cohorts I and II, the AUC values of the baseline model, including sex and age were 0.726 (95% CI: 0.711–0.741) and 0.659 (95% CI: 0.622–0.696), respectively (Supplementary Figure 2A and Supplementary Table S6). Adding PGS to the model resulted in slight improvements, with AUC values of 0.728 (95% CI: 0.713–0.743) and 0.664 (95% CI: 0.627–0.701) in validation cohorts I and II, respectively (Supplementary Figure 2A and Supplementary Table S6).

We assessed the association between the T-score PGS and osteoporosis using multivariable models in the two validation cohorts (Supplementary Figure 2B and Supplementary Table S7). A fixed-effect model indicated minimal intercohort heterogeneity for the PGS effect (I^2 = 0%, Cochran's Q = 0.02, P for heterogeneity = 0.878). Accordingly, we report the fixed-effect pooled estimate. Each 1.0-unit increase in the normalized PGS was associated with 12% lower odds of osteoporosis (OR = 0.88, 95% CI: 0.83–0.94, $P = 2.77 \times 10^{-5}$), indicating an inverse association between the T-score PGS and osteoporosis risk. In addition, the odds of osteoporosis increased by 7% per year of age (OR = 1.07, 95% CI: 1.07–1.08, $P = 3.03 \times 10^{-115}$), and were 1.84-fold higher in females than in males (OR = 1.84, 95% CI: 1.57–2.17, $P = 2.02 \times 10^{-13}$).

Osteoporosis risk prediction using T-score PGS

For further analysis, individuals in the validation cohorts were stratified into quintiles using the PGS. In the fixed-effect meta-analysis of the two validation cohorts, individuals in the lowest PGS quintile (Q1)—which also had the lowest mean T-score (Supplementary Table S8)—had a significantly increased risk of developing osteoporosis compared to the intermediate PGS quintile (Q3) (Table 2). Moreover, the OR for Q2 was significantly higher than that for Q3 (Table 2). In contrast, the highest PGS quintile (Q5)—which had the highest

331 mean T-score (Supplementary Table S8)—was associated with a significantly lower risk of
332 osteoporosis than Q3 (Table 2).
333
334 **Osteoporosis genetic risk stratification by T-score PGS: Joint effects of age group,**
335 **sex, and modifiable factors**
336 To evaluate the influence of age and sex on the genetic risk of osteoporosis, we
337 stratified participants at the clinically relevant threshold of 65 years, as recommended by
338 osteoporosis guidelines for the Dual-energy X-ray Absorptiometry-based screening.[35] Using
339 individuals with intermediate (Q2–Q4) PGS as the reference group, we compared the risk of
340 osteoporosis across the genetic risk categories (Figure 3 and Supplementary Table S9). In
341 the fixed-effect meta-analysis, younger individuals (<65 years) with a lower genetic risk (Q5)
342 showed significantly reduced odds of osteoporosis compared with the reference (OR = 0.74,
343 95% CI: 0.59–0.92, P = 0.006). Among older participants (≥65 years), those with a high
344 genetic risk (Q1) exhibited significantly increased odds of osteoporosis compared to the
345 reference (OR = 1.30, 95% CI: 1.04–1.62, P = 0.019). These findings suggest that a low
346 genetic risk is more detectable in younger individuals, whereas a high genetic risk becomes
347 evident in those aged ≥65 years.
348 We then performed additional stratification according to sex. In women, the pattern
349 was consistent with the overall findings: those with low genetic risk (Q5) had a significantly
350 reduced odds of osteoporosis in the <65 group (OR = 0.74, 95% CI: 0.57–0.95, P = 0.017),
351 while those ≥65 years with high genetic risk (Q1) showed increased odds compared with the
352 reference group (OR = 1.42, 95% CI: 1.08–1.86, P = 0.012). However, in men, no significant
353 differences in osteoporosis odds were observed across genetic risk categories within age
354 groups.
355 Subsequently, we assessed the effects of modifiable lifestyle factors. Stratification
356 by established risk factors—including obesity, smoking, high alcohol intake, and physical
357 inactivity—did not show significant modification of genetic risk (Supplementary Figure S3 and

358 Supplementary Table S10).

359

360 **Prospective cohort analysis**

361 During the follow-up period, the corresponding person-years of observation for
362 validation cohorts I and II were 16,226.8 and 1,901.6, respectively. During the follow-up
363 period, 422 of 4,811 participants in validation cohort I and 116 of 581 in validation cohort II
364 developed new cases (Supplementary Table S11). In both cohorts, the cumulative incidence
365 of osteoporosis was highest in the genetic high-risk group (Q1) and lowest in the low-risk
366 group (Q5), with the incidence rate showing a similar trend (Table 3). In the meta-analysis of
367 IRR, the high-risk group (Q1) showed a significantly elevated risk compared with the
368 intermediate group (Q2-Q4), whereas the low-risk group (Q5) showed a significantly reduced
369 risk (Table 3).

370

371 **Interaction of age with genetic risk of T-score and osteoporosis**

372 We examined whether the predictive effect of PGS on osteoporosis varied with age.
373 Interaction terms for age × PGS were tested using logistic regression models with
374 osteoporosis as the outcome, including sex as a covariate. None of the interaction terms
375 reached statistical significance, indicating that the effect of PGS on osteoporosis was
376 consistent across different ages (Supplementary Table S12).

377 We then assessed the correlation between baseline age and T-score separately by
378 genetic risk group, comparing each group with the intermediate-risk group (Supplementary
379 Figure S4). No significant differences were observed in either the high- or low-risk groups,
380 and the slope of the association did not differ significantly between the groups
381 (Supplementary Table S13). These results suggest that the PGS was not associated with the
382 rate of age-related T-score decline.

383 We next used the fitted age–T-score regression lines to estimate group-specific
384 mean T-scores at age 20 years as an approximation of peak bone mass. When extrapolating

385 the linear regression model to age 20 years, the predicted mean T-score differed significantly
386 by genetic risk group: relative to the intermediate-risk group, the low-risk group showed a
387 positive deviation, whereas the high-risk group showed a negative deviation (Supplementary
388 Table S14). Consistent with this pattern, analyses of observed T-scores at baseline among
389 participants aged 20–44 years (young adult range) showed a modest, non-significant trend
390 toward lower values in the high-risk group and significantly higher values in the low-risk group
391 compared with the intermediate-risk group (Table 4). These findings suggest that high-
392 genetic risk primarily lowers the BMD trajectory from early adulthood, rather than accelerating
393 age-related bone loss, so that parallel declines over time cause these individuals to reach
394 the osteoporotic range earlier.
395

396 **Discussion**

397 Most polygenic models for bone traits have been developed using European
398 cohorts.[5,9,10] Given ancestry differences, portability across populations remains a key
399 challenge, despite recent efforts toward cross-ancestry models.[36,37] Although our Japanese-
400 specific model may not directly integrate into multi-ancestry frameworks, it provides one of
401 the first large-scale polygenic tools for osteoporosis risk in East Asians and may serve as a
402 valuable option in this population.

403 In this study, we developed and validated a Japanese-specific PGS model for
404 osteoporosis in a large-scale cohort. Given known ancestry differences in allele frequencies,
405 linkage disequilibrium structure, and environmental exposures, such population-tailored
406 scores are likely to perform better than PGSs derived exclusively from European cohorts in
407 East Asian populations. Our GWAS identified three loci—*MBL2, TMEM135*, and *WNT16*—
408 which have also been reported in previous GWASs in both European and East Asian
409 populations.[5,9,38,39] The concordance of these loci across populations, together with their
410 involvement in bone-metabolism pathways,[8] supports the reliability of our GWAS and its use
411 as a basis for constructing a PGS in East Asians.

The predictive performance of our model (AUC ~0.73) was comparable to that of European-derived models.[5,10] Our model explained approximately 20–24% of the variance in QUS-derived T-scores, a proportion consistent with previous large-scale studies using similar methods.[9] These results highlight the potential clinical utility of a population-specific polygenic tools for the early identification of osteoporosis risk.

Although no statistically significant interaction between age and PGS was detected in logistic regression models, subgroup analyses revealed clinically meaningful patterns. Age-stratified odds ratios indicated that individuals at high genetic risk had an increased likelihood of osteoporosis in older age, even in the absence of a formal interaction term. Together with the lack of differences in the slope of the age–T-score association across genetic risk groups, these findings suggest that the PGS is not strongly associated with the rate of age-related T-score decline.

Taken together, the observed age-stratified odds ratios and the contrasts in predicted and observed T-scores in young adults support a model in which high-genetic risk primarily lowers the bone mass trajectory from early adulthood, rather than accelerating age-related bone loss. Under this model, parallel age-related declines across PGS groups mean that individuals at high genetic risk are more likely to cross the osteoporotic threshold earlier in later life. This interpretation is in line with previous observations that many BMD-associated genetic variants exert stronger effects during the bone accrual phase in youth,[7] and is concordant with pediatric data showing that a BMD-related polygenic score is associated with higher BMD and reduced fracture risk in childhood,[40] as also highlighted by Fiscaletti and Manousaki.[41]

This interpretation is clinically relevant. Peak bone mass has long-term implications for osteoporosis development, and individuals with a high genetic risk may inherently have a lower bone mass established during early adulthood. Therefore, early identification and intervention before the onset of bone loss may be the most effective. The absence of a statistical interaction should not be viewed as evidence against clinical relevance; instead,

our findings underscore the importance of age-stratified analyses and large-scale cohorts in detecting subtle yet meaningful gene-environment dynamics.

This study had some limitations. First, data on prior osteoporosis treatment were unavailable, and participants undergoing therapy at baseline may not have been excluded. Second, recruitment was limited to participants from health check-ups and community support centers in Miyagi and Iwate Prefectures, potentially introducing a health-conscious selection bias.[20-22] Third, key lifestyle factors (e.g., alcohol use, smoking, and physical activity) were assessed by self-report, which may have affected accuracy. In addition, most participants were middle-aged or older, and although lifestyle interventions can increase or maintain BMD to some extent even in older adults, their effects are generally considered small [1,42]. This does not argue against the importance of lifestyle, but rather may reflect the limited plasticity of BMD once peak bone mass has been established. Our findings therefore support a prevention strategy that combines early identification of genetically susceptible individuals with lifelong optimization of lifestyle factors.

In conclusion, we established a polygenic score for osteoporosis risk in a Japanese cohort and validated its performance. Our findings suggest that this score primarily reflects genetically determined peak bone mass, such that high-risk individuals enter adulthood with lower BMD levels and, despite similar rates of decline, reach the osteoporotic threshold earlier. These observations support the use of polygenic information to identify susceptible individuals at an early stage and to focus bone-preserving lifestyle strategies particularly before the attainment of peak bone mass. However, further studies are needed to determine whether PGS-based interventions initiated in childhood or adolescence can reduce the risk of osteoporosis.

Acknowledgements

This study was supported by the Tohoku Medical Megabank (TMM) Project (Special Account for the Reconstruction of the Great East Japan Earthquake) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical Research and Development (AMED) under grant number JP23tm0124006. The supercomputer system in the TMM Project under grant number JP21tm0424601 was used for data analysis. YOY and AS were supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant JP23K09696.

Supplementary information

Supplementary information is available with the preprint on medRxiv.

References

1. Bouvard B, Annweiler C, Legrand E. Osteoporosis in older adults. Joint Bone Spine. 2021;88(3):105135. Epub 20210121. doi: 10.1016/j.jbspin.2021.105135
2. Mori T, Komiyama J, Fujii T, Sanuki M, Kume K, Kato G, et al. Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims database. Arch Osteoporos. 2022;17(1):61. Epub 20220411. doi: 10.1007/s11657-022-01096-8
3. Zhu X, Bai W, Zheng H. Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. Bone Res. 2021;9(1):23. Epub 20210429. doi: 10.1038/s41413-021-00143-3
4. Abe K, Inage K, Yoshimura K, Sato D, Yamashita K, Yamashita M, et al. Deaths caused by osteoporotic fractures in Japan: An epidemiological study. J Orthop Sci. 2024;29(6):1477–82. Epub 20231118. doi: 10.1016/j.jos.2023.10.013
5. Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS One. 2018;13(7):e0200785. Epub 20180726. doi: 10.1371/journal.pone.0200785

492 6. Hereford T, Kellish A, Samora JB, Reid Nichols L. Understanding the importance of peak
493 bone mass. JPOSNA. 2024;7:100031. Epub 20240405. doi:
494 10.1016/j.jposna.2024.100031
495 7. Medina-Gomez C, Kemp JP, Trajanoska K, Luan J, Chesi A, Ahluwalia TS, et al. Life-
496 Course Genome-wide Association Study Meta-analysis of Total Body BMD and
497 Assessment of Age-Specific Effects. Am J Hum Genet. 2018;102(1):88–102. doi:
498 10.1016/j.ajhg.2017.12.005
499 8. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic
500 influences on osteoporosis in humans and mice. Nat Genet. 2019;51(2):258–66. Epub
501 20181231. doi: 10.1038/s41588-018-0302-x
502 9. Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp JP, et al.
503 Development of a polygenic risk score to improve screening for fracture risk: A genetic
504 risk prediction study. PLoS Med. 2020;17(7):e1003152. Epub 20200702. doi:
505 10.1371/journal.pmed.1003152
506 10. Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, et al. Improved
507 prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Med.
508 2021;13(1):16. Epub 20210203. doi: 10.1186/s13073-021-00838-6
509 11. Wu Q, Jung J. Genome-wide polygenic risk score for major osteoporotic fractures in
510 postmenopausal women using associated single nucleotide polymorphisms. J Transl
511 Med. 2023;21(1):127. Epub 20230216. doi: 10.1186/s12967-023-03974-2
512 12. Kim DJ, Kang JH, Kim JW, Cheon MJ, Kim SB, Lee YK, et al. Evaluation of optimal
513 methods and ancestries for calculating polygenic risk scores in East Asian population.
514 Sci Rep. 2023;13(1):19195. Epub 20231106. doi: 10.1038/s41598-023-45859-w
515 13. Lee SH, Lee SW, Ahn SH, Kim T, Lim KH, Kim BJ, et al. Multiple gene polymorphisms
516 can improve prediction of nonvertebral fracture in postmenopausal women. J Bone Miner
517 Res. 2013;28(10):2156–64. doi: 10.1002/jbmr.1955
518 14. Lin YJ, Liang WM, Chiou JS, Chou CH, Liu TY, Yang JS, et al. Genetic predisposition to
519 bone mineral density and their health conditions in East Asians. J Bone Miner Res.
520 2024;39(7):929–41. doi: 10.1093/jbmr/zjae078

521 15. Prive F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, et al. Portability of 245
522 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups
523 from the same cohort. Am J Hum Genet. 2022;109(1):12–23. doi:
524 10.1016/j.ajhg.2021.11.008
525 16. Li YM, Peng C, Zhang JG, Zhu W, Xu C, Lin Y, et al. Genetic risk factors identified in
526 populations of European descent do not improve the prediction of osteoporotic fracture
527 and bone mineral density in Chinese populations. Sci Rep. 2019;9(1):6086. Epub
528 20190415. doi: 10.1038/s41598-019-42606-y
529 17. Chen JJ, Chen IC, Wei CY, Lin SY, Chen YM. Utilize polygenic risk score to enhance
530 fracture risk estimation and improve the performance of FRAX in patients with
531 osteoporosis. Arch Osteoporos. 2023;18(1):147. Epub 20231201. doi: 10.1007/s11657-
532 023-01357-0
533 18. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic Risk,
534 Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med.
535 2016;375(24):2349–58. Epub 20161113. doi: 10.1056/NEJMoa1605086
536 19. Yang YQ, Yu XH, Bo L, Lei SF, Deng FY. Genetic Risk for Osteoporosis and the Benefit
537 of Adherence to Healthy Lifestyles. Int J Public Health. 2022;67:1605114. Epub 20220913.
538 doi: 10.3389/ijph.2022.1605114
539 20. Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, et al. The Tohoku
540 Medical Megabank Project: Design and Mission. J Epidemiol. 2016;26(9):493–511. Epub
541 20160702. doi: 10.2188/jea.JE20150268
542 21. Hozawa A, Tanno K, Nakaya N, Nakamura T, Tsuchiya N, Hirata T, et al. Study Profile of
543 the Tohoku Medical Megabank Community-Based Cohort Study. J Epidemiol.
544 2021;31(1):65–76. Epub 20200111. doi: 10.2188/jea.JE20190271
545 22. Hozawa A, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, et al. Progress
546 Report of the Tohoku Medical Megabank Community-based Cohort Study: Study Profile
547 of the Repeated Center-based Survey During Second Period in Miyagi Prefecture. J
548 Epidemiol. 2024;34(9):434–43. Epub 20240731. doi: 10.2188/jea.JE20230241

549 23. Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yageta M, Motoike IN, et al.
550 Genome analyses for the Tohoku Medical Megabank Project towards establishment of
551 personalized healthcare. J Biochem. 2019;165(2):139–58. doi: 10.1093/jb/mvy096
552 24. Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, et al. Biobank
553 Establishment and Sample Management in the Tohoku Medical Megabank Project.
554 Tohoku J Exp Med. 2019;248(1):45–55. doi: 10.1620/tjem.248.45
555 25. Sakurai-Yageta M, Kumada K, Gocho C, Makino S, Uruno A, Tadaka S, et al. Japonica
556 Array NEO with increased genome-wide coverage and abundant disease risk SNPs. J
557 Biochem. 2021;170(3):399–410. doi: 10.1093/jb/mvab060
558 26. Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Healthy
559 lifestyle practice correlates with decreased obesity prevalence in individuals with high
560 polygenic risk: TMM CommCohort study. J Hum Genet. 2025;70(1):9–15. Epub
561 20240822. doi: 10.1038/s10038-024-01280-3
562 27. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
563 biobank-scale datasets. Nat Genet. 2018;50(7):906–8. doi: 10.1038/s41588-018-0144-6
564 28. Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, et al. 3.5KJPNv2: an allele
565 frequency panel of 3552 Japanese individuals including the X chromosome. Hum
566 Genome Var. 2019;6:28. Epub 20190618. doi: 10.1038/s41439-019-0059-5
567 29. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The
568 mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
569 2020;581(7809):434–43. Epub 20200527. doi: 10.1038/s41586-020-2308-7
570 30. Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al.
571 LocusZoom.js: interactive and embeddable visualization of genetic association study
572 results. Bioinformatics. 2021;37(18):3017–8. doi: 10.1093/bioinformatics/btab186
573 31. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
574 specific haplotype structure and linking correlated alleles of possible functional variants.
575 Bioinformatics. 2015;31(21):3555–7. Epub 20150702. doi: 10.1093/bioinformatics/btv402
576 32. Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Genetic
577 predisposition for immunoglobulin E production explains atopic risk in children: Tohoku

578 Medical Megabank cohort study. Am J Hum Genet. 2025;112(8):1852–1863. Epub
579 20250721. doi: 10.1016/j.ajhg.2025.06.015
580 33. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression
581 and continuous shrinkage priors. Nat Commun. 2019;10(1):1776. Epub 20190416. doi:
582 10.1038/s41467-019-09718-5
583 34. Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling
584 Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J Hum Genet.
585 2015;97(4):576–92. doi: 10.1016/j.ajhg.2015.09.001
586 35. Ward RJ, Roberts CC, Bencardino JT, Arnold E, Baccei SJ, Cassidy RC, et al. ACR
587 Appropriateness Criteria® Osteoporosis and Bone Mineral Density. J Am Coll Radiol.
588 2017;14(5S):S189–S202. doi: 10.1016/j.jacr.2017.02.018
589 36. Kelemen M, Vigorito E, Fachal L, Anderson CA, Wallace C. shaPRS: Leveraging shared
590 genetic effects across traits or ancestries improves accuracy of polygenic scores. Am J
591 Hum Genet. 2024;111(6):1006–17. Epub 20240503. doi: 10.1016/j.ajhg.2024.04.009
592 37. Moreno-Grau S, Vernekar M, Lopez-Pineda A, Mas-Montserrat D, Barrabes M, Quinto-
593 Cortes CD, et al. Polygenic risk score portability for common diseases across genetically
594 diverse populations. Hum Genomics. 2024;18(1):93. Epub 20240902. doi:
595 10.1186/s40246-024-00664-y
596 38. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-
597 population atlas of genetic associations for 220 human phenotypes. Nat Genet.
598 2021;53(10):1415–24. Epub 20210930. doi: 10.1038/s41588-021-00931-x
599 39. Lu HF, Hung KS, Chu HW, Wong HS, Kim J, Kim MK, et al. Meta-Analysis of Genome-
600 Wide Association Studies Identifies Three Loci Associated With Stiffness Index of the
601 Calcaneus. J Bone Miner Res. 2019;34(7):1275–83. Epub 20190319. doi:
602 10.1002/jbmr.3703
603 40. Mitchell JA, Bradfield J, McCormack SE, Chesi A, Kalkwarf HJ, Lappe JM, et al. The
604 gSOS Polygenic Score is Associated with Bone Density and Fracture Risk in Childhood.
605 J Bone Miner Res. 2025. Epub 20251014. doi: 10.1093/jbmr/zjaf149

606 41. Fiscaletti M, Manousaki D. Validation of a Polygenic Score for Bone Health-Related
607 Outcomes in Childhood. J Bone Miner Res. 2025. Epub 20251010. doi:
608 10.1093/jbmr/zjaf146
609 42. Bonjour JP, Gueguen L, Palacios C, Shearer MJ, Weaver CM. Minerals and vitamins in
610 bone health: the potential value of dietary enhancement. Br J Nutr. 2009;101(11):1581–
611 96. Epub 20090401. doi: 10.1017/S0007114509311721
612
613

Table 1. Lead variants identified in the genome-wide association study of QUS-derived T-score in the Japanese population.

rsID (Lead SNP)	CHR	BP	Near Gene	TMM18K-JPAv2							GCST006433						
				EA	NEA	EAF	Beta	SE	*P* value	INFO	EA	NEA	EAF	Beta	SE	*P* value	INFO
rs71032654; rs200903639	10	54,429,192	*MLB2*	TAC	TATATATATATATATATATACAC	0.649	0.091	0.015	**5.70E-10**	0.935	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
rs2451053	11	86,853,548	*TMEM135*	T	C	0.678	-0.088	0.014	**1.10E-09**	0.999	T	C	0.471	-0.043	0.002	**7.70E-97**	0.998
rs10254825	7	120,956,440	*WNT16*	G	A	0.445	0.081	0.014	**8.30E-09**	0.941	G	A	0.395	0.182	0.002	**3.0E-1601**	0.980

Variants were filtered based on minor allele frequency (MAF ≥0.01) and imputation INFO score (≥0.4). Effect alleles (EA) and non-effect alleles (NEA), along with corresponding effect sizes (Beta), from the GCST006433 GWAS summary statistics were re-aligned and recalculated using gnomAD v2.1 (GRCh37) to harmonize allele orientation with the TMM18K-JPAv2 dataset. Bold indicates statistical significance ($P < 5 \times 10^{-8}$). Abbreviations: *BP,* base position; *CHR*, chromosome; *EAF*, effect allele frequency; *INFO*, imputation quality score; *JPAv2*, Japonica Array version 2 ; *MBL2*, mannose-binding lectin 2; *n.d.*, not detected; *SE*, standard error; *TMEM135*, transmembrane protein 135; *TMM*, Tohoku Medical Megabank; *WNT16*, Wnt family member 16.

Table 2. Osteoporosis prevalence and odds ratio stratified by PGS quintile in baseline study.

	PGS (quintile)	Number of subjects (n)	Number of cases (n)	Prevalence (%)	OR	95%CI		*P* value	*P* for trend	Cochran's Q	I^2 (%)	p_{het}
						Low	High					
Validation cohort I (TMM9K-JPAv2, N=7,609)	Q1	1,522	289	19.0	1.24	1.02	1.51	**0.032**		–	–	–
	Q2	1,522	273	17.9	1.17	0.96	1.43	0.116		–	–	–
	Q3	1,521	240	15.8	1.00 (Reference)	–	–	–	**2.37E-04**	–	–	–
	Q4	1,522	263	17.3	1.06	0.87	1.30	0.556		–	–	–
	Q5	1,522	221	14.5	0.86	0.70	1.05	0.142		–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	Q1	213	49	23.0	1.02	0.64	1.62	0.940		–	–	–
	Q2	212	46	21.7	0.89	0.55	1.42	0.615		–	–	–
	Q3	212	49	23.1	1.00 (Reference)	–	–	–	0.490	–	–	–
	Q4	212	45	21.2	0.92	0.57	1.47	0.714		–	–	–
	Q5	212	44	20.8	0.83	0.52	1.33	0.443		–	–	–
Fixed-effect meta-analysis	Q1	–	–	–	1.22	1.07	1.40	**0.003**		0.64	0.0	0.72
	Q2	–	–	–	1.15	1.00	1.31	**0.047**		1.26	0.0	0.53
	Q3	–	–	–	1.00 (Reference)	–	–	–	–	–	–	–
	Q4	–	–	–	1.05	0.92	1.20	0.489		0.35	0.0	0.84
	Q5	–	–	–	0.85	0.74	0.98	**0.027**		0.01	0.0	0.99

Odds ratios for osteoporosis at baseline were estimated using logistic regression adjusted for age and sex. Pooled estimates were obtained using fixed-effects meta-analysis. Bold indicates statistical significance ($P < 0.05$). Abbreviations: *CI*, confidence interval; I^2, percentage of variation due to heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; OR, odds ratio; P_{het}, *P* value for heterogeneity; *PGS*, polygenic score; *TMM*, Tohoku Medical Megabank. Q indicates quintile.

Table 3. Incidence and risk estimates of osteoporosis by PGS-based genetic risk group in the follow-up study.

	Genetic risk [quintile]	n at risk	Cases	Person-years	Cumulative incidence (%)	95%CI		Incidence rate (/1,000 PY)	95%CI		IRR	95%CI		*P* value	Cochran's Q	I^2 (%)	P_{het}
						Low	High		Low	High		Low	High				
Validation cohort I TMM9K-JPAv2 (N=4,811)	High [Q1]	914	116	3032.7	12.7	10.6	15.0	38.2	31.6	45.9	1.45	1.16	1.80	**9.30E-04**	–	–	–
	Intermediate [Q2 - Q4]	2,910	260	9815.6	8.9	7.9	10.0	26.5	23.4	29.9	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	987	66	3378.5	6.7	5.2	8.4	19.5	15.1	24.9	0.74	0.57	0.97	**0.030**	–	–	–
Validation cohort II TMM18K-JPANEO (N=581)	High [Q1]	115	30	357.4	26.1	18.3	35.1	83.9	56.6	119.8	1.33	0.87	2.03	0.188	–	–	–
	Intermediate [Q2 - Q4]	356	74	1161.1	20.8	16.7	25.4	63.7	50.0	80.0	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	110	12	383.0	10.9	5.8	18.3	31.3	16.2	54.7	0.51	0.28	0.94	**0.030**	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	–	–	–	–	–	–	1.42	1.17	1.73	**3.89E-04**	0.12	0.0	0.73
	Intermediate [Q2 - Q4]	–	–	–	–	–	–	–	–	–	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	–	–	–	–	–	–	–	–	–	0.70	0.54	0.89	**0.004**	1.23	18.6	0.27

IRR for incident osteoporosis during the follow-up period was estimated using logistic regression adjusted for age and sex. Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance ($P < 0.05$).

Abbreviations: *CI*, confidence interval; I^2, percentage of variation due to heterogeneity; *IRR*, incidence rate ratios; *JPANEO*,

Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, *P* value for heterogeneity; *PGS*, polygenic score; *PY*, person-years; *TMM*, Tohoku Medical Megabank.

Table 4. Differences in observed T-score at baseline (age 20-44, young adult range) for high- and low-generic risk groups versus the intermediate-risk group (Q2–Q4).

overall	Genetic risk [quintile]	n	Observed T-score		Difference in observed T-score vs Intermediate group (group − intermediate)							
			Mean	SD	Mean	SE	95%CI		*P* value	Cochran's Q	I² (%)	P*het*
							Low	High				
Validation cohort I (TMM9K-JPAv2, N=7,609)	High [Q1]	314	-0.831	1.140	-0.135	0.076	-0.283	0.014	**0.038**	–	–	–
	Intermediate [Q2 - Q4]	898	-0.696	1.193	–	–	–	–	–	–	–	–
	Low [Q5]	279	-0.439	1.184	0.257	0.081	0.098	0.417	**0.001**	–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	High [Q1]	48	-0.891	1.031	-0.118	0.186	-0.487	0.251	0.264	–	–	–
	Intermediate [Q2 - Q4]	122	-0.773	1.236	–	–	–	–	–	–	–	–
	Low [Q5]	42	-0.831	1.230	-0.059	0.220	-0.498	0.380	0.605	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	-0.133	0.070	-0.270	0.005	0.059	0.01	0	0.93
	Low [Q5]	–	–	–	0.219	0.076	0.070	0.369	**0.004**	1.81	44.8	0.18

The differences in observed T-score values at age 20-44 (young adult range) for the high- and low-risk groups compared with the intermediate-risk group (reference). Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance ($p < 0.05$). Abbreviations: *CI*, confidence interval; I^2, percentage of variation due to

heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, *P* value for heterogeneity; *PGS*, polygenic score; *TMM*, Tohoku Medical Megabank.

Figure legends

Figure 1. Study design.

Two TMM cohorts (9K and 18K) [20-22] were split by genotyping array—Axiom Japonica Array v2 (JPAv2) [23,24] and NEO (JPANEO) [25]—into four independent subgroups (TMM18K-JPAv2, TMM18K-JPANEO, TMM9K-JPAv2, TMM9K-JPANEO). QUS-derived T-score GWAS was conducted in TMM18K-JPAv2 to derive variant weights; model selection was performed in TMM9K-JPANEO (Phase 1). The final PGS was evaluated in two independent validation cohorts: I (TMM9K-JPAv2) and II (TMM18K-JPANEO). Each cohort underwent (Phase 2) cross-sectional analysis at baseline (excluding participants with missing T-scores, extreme baseline T-scores (outside the range −4.0 to +4.0 SD), or missing covariates) and (Phase 3) prospective analysis using follow-up data with additional exclusions (no follow-up, baseline T-score ≤–2.5 SD, fracture history, self-reported osteoporosis at follow-up, or extreme baseline T-scores (outside the range −4.0 to +4.0 SD)). Final sample sizes were 7,609 and 1,061 for cross-sectional, and 4,811 and 581 for prospective analyses in validation cohorts I and II, respectively. All four subgroups were independent. Abbreviations: GWAS, genome-wide association study; JPANEO, Japonica array NEO; JPAv2, Japonica array version 2; PGS, polygenic score; PRS-CS, polygenic risk score—continuous shrinkage method; P+T, pruning and thresholding method; SD, standard deviation; TMM, Tohoku Medical Megabank.

Figure 2. Model selection of T-score PGSs.

(A) Discriminative performance (ρ) of 37 candidate models generated using P+T, LDpred, and PRS-CS methods. PRS-CS (φ = “auto”) showed the highest ρ (ρ = 0.147, $P = 2.94 \times 10^{-8}$). (B) Correlation of PGSs between the model selection cohort (TMM9K-JPANEO) and validation cohorts I and II (TMM9K-JPAv2 and TMM18K-JPANEO). Scatterplots show the relationship between normalized PGSs (x-axis) and age- and sex-adjusted T-scores (y-axis). Dashed lines represent fitted linear regression lines with 95% confidence intervals.

641 Color gradients indicate sample density. *P* values are from linear regression analyses.
642 Abbreviations: PGS, polygenic score; PRS-CS, polygenic risk score—continuous shrinkage
643 method; P+T, pruning and thresholding method.
644
645 **Figure 3. Osteoporosis prevalence and odds ratio stratified by age-stratified genetic**
646 **risk groups.**
647 Participants were stratified by genetic risk (Q1: high, Q2–Q4: intermediate, Q5: low)
648 and age (<65 or ≥65 years). The individuals with the intermediate [Q2–Q4] PGS group served
649 as reference. Osteoporosis prevalence (left and middle) and odds ratios (right) at baseline
650 were estimated using logistic regression adjusted for age and sex, with pooled results via
651 fixed-effect meta-analysis. Bars indicate 95% confidence intervals. The bar color indicates
652 the status of genetic risk levels. † indicates a significant trend across genetic risk groups (P
653 < 0.05). * indicates a statistically significant pooled odds ratio from the fixed-effect meta-
654 analysis (P < 0.05). Abbreviations: PGS, polygenic score; Q, quintile.
655

Figure 1. Otsuka-Yamasaki et. al



Figure 2. Otsuka-Yamasaki et. al



Figure 3. Otsuka-Yamasaki et. al